The Current State of the Treatment of Kidney Cancer
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, provides an overview of the treatment of kidney cancer.
Clinical Pearls
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, provides an overview of the treatment of kidney cancer.
- The treatment of kidney cancer can be divided into two categories: anti-angiogenic therapies and mTOR inhibitors.
- Before 2007, the main treatment options were interferon and interleukin-2.
- Many drugs have been approved since 2007, including sorafenib, axitinib, sunitinib, pazopanib, bevacizumab, temsirolimus, and everolimus.
- About 75-80% of patients with kidney cancer have clear cell-type disease.
- Today, no standard of care exists for rare types of kidney cancer.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
